Peg-Intron peginterferon alfa-2b: Phase IIIb data

Top-line results from the open-label, Phase IIIb U.S. IDEAL trial in 3,070 patients with previously untreated HCV genotype 1 showed that SVR rates, the primary endpoint, were comparable between patien...